Hindustan Laboratories, a manufacturer of generic medicines, has announced an initial public offering (IPO) comprising a fresh issue of 50 lakh shares and an offer for sale (OFS) of 91 lakh shares by its sole promoter, Rajesh Vasantray Doshi.
The company plans to utilise Rs 72.5 crore from the fresh issue for working capital requirements, with the remaining proceeds allocated to general corporate purposes. Choice Capital Advisors has been appointed as the IPO’s merchant banker.
Company Overview:
Incorporated in 2017, Hindustan Laboratories manufactures generic formulations—medicines whose patents have expired and serve as affordable alternatives to branded drugs. The company primarily supplies products under procurement contracts for the Ministry of Health and Family Welfare via central and state government agencies.
As of September 2025, the company offered 948 products across therapeutic segments including anti-allergic, anti-diabetic, anti-infective, anti-malarial, cardiac, gastrointestinal, nutritional, and pain management categories.
Financial Performance:
- H1 FY26 (ending September 2025): Revenue Rs 112.6 crore; Profit Rs 18.2 crore
- FY2025: Revenue Rs 219.7 crore (+17.9% YoY); Profit Rs 41.3 crore (+21% YoY)
Hindustan Laboratories competes with listed peers such as Ajanta Pharma, Syncom Formulations, and Windlas Biotech.
The IPO will provide investors an opportunity to participate in the growth of a government-focused generics supplier as the company looks to expand its working capital and strengthen its operations in the growing Indian pharmaceutical market.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult a financial advisor before participating in the IPO.
